![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in
USD28.46
USD58.46
Pay in 4 interest-free payments of $7.12 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-025-03774-9/MediaObjects/41591_2025_3774_Fig3_HTML.png)
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3731860835866315291)
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=9169782036482424)
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=3749192091824733)
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide on ingestive behavior in](https://www.ovid.com/image-api/imgsrv/article/i/thumb/wkmrid/JOURNAL%252Fnejm%252F04.03%252F00006024-202207210-00005%252Ffigure1-5%252Fv%252F2026-01-21T143010Z%252Fr%252Fimage-jpeg/width/600.png)
